Literature DB >> 25651743

Prostaglandin F2 alpha plasma concentration predicts glycemic control and oxidation status in patients with type 2 diabetes mellitus.

Manouchehr Nakhjavani, Zaniar Ghazizadeh, Arash Aghajani Nargesi, Abnous Mokhtari, Firuzeh Asgarani, Mehrnaz Imani, Zahra Davoudi, Alireza Esteghamati.   

Abstract

BACKGROUND: 8-iso-PGF2α is a family of PGF2α that could be offered as a non-invasive tool to represent in vivo oxidation status, as a link between oxidative milieus and vascular dysfunction.
METHODS: A total of 45 patients with type 2 diabetes and 45 healthy adults were studied in this cross-sectional analysis. Blood samples were collected to measure the level of lipid profile, oxidative stress, and glycemic control indices. The sensitivity and specificity of 8-iso-PGF2α as a screening test were analyzed in the cut-off range 252 - 377.5 pg/mL and the corresponding receiver operating characteristics (ROC) were plotted to assess performance of the test.
RESULTS: 8-iso-PGF2α level was significantly higher in the diabetic group (439.11 pg/mL ± 181.13 vs. 380.93 pg/mL ± 146.52). After adjustments for age, gender, and body mass index (BMI), linear regression analysis revealed that homeostasis model assessment of insulin resistance (HOMA-IR), blood pressure, fasting blood sugar (FBS), serum creatinine, insulin, oxLDL, and CRP levels are directly correlated with 8-iso-PGF2α in the 25% - 75% quartiles. Moreover, their mean levels were higher in quartiles with greater 8-iso-PGF2α levels. The cut-offs showing the best equilibrium between sensitivity and specificity approached 269.5 pg/mL with 83% and 62.5% sensitivity and specificity, respectively.
CONCLUSIONS: Our study provides evidence for the application of serum 8-isoPGF2α in the 25 - 75% quartile ranges to screen for the severity of oxidative reactions and glycemic control in vivo without need for any further in vitro enzymatic reactions, with higher levels, reflecting more severe oxidation and poor glycemic control.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25651743     DOI: 10.7754/clin.lab.2014.140405

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  6 in total

1.  Urine Eicosanoids in the Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial.

Authors:  Catherine N Le; Todd Hulgan; Chi-Hong Tseng; Ginger L Milne; Jordan E Lake
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

2.  Intronic Variants in OCT1 are Associated with All-Cause and Cardiovascular Mortality in Metformin Users with Type 2 Diabetes.

Authors:  Natascha Schweighofer; Bernd Genser; Winfried Maerz; Marcus E Kleber; Olivia Trummer; Thomas R Pieber; Barbara Obermayer-Pietsch
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-18       Impact factor: 3.168

3.  The effects of Jerusalem artichoke and fermented soybean powder mixture supplementation on blood glucose and oxidative stress in subjects with prediabetes or newly diagnosed type 2 diabetes.

Authors:  Hyeon Yeong Ahn; Minjoo Kim; Cho Rong Seo; Hye Jin Yoo; Sang-Hyun Lee; Jong Ho Lee
Journal:  Nutr Diabetes       Date:  2018-07-19       Impact factor: 5.097

4.  Associations of plasma 8-iso-prostaglandin Flevels with fasting blood glucose (FBG) and intra-abdominal fat (IAF) area in various Glycometabolism populations.

Authors:  Ning Ma; Yujian Zhang; Binbin Liu; Xiaojiao Jia; Rui Wang; Qiang Lu
Journal:  BMC Endocr Disord       Date:  2021-10-28       Impact factor: 2.763

5.  Influence of estrogen-related receptor γ (ESRRG) rs1890552 A > G polymorphism on changes in fasting glucose and arterial stiffness.

Authors:  Minjoo Kim; Hye Jin Yoo; Minkyung Kim; Haengok Seo; Jey Sook Chae; Sang-Hyun Lee; Jong Ho Lee
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

6.  Genetic risk score of common genetic variants for impaired fasting glucose and newly diagnosed type 2 diabetes influences oxidative stress.

Authors:  Minjoo Kim; Minkyung Kim; Limin Huang; Sun Ha Jee; Jong Ho Lee
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.